Compare AR & TECH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AR | TECH |
|---|---|---|
| Founded | 2002 | 1976 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8B | 9.1B |
| IPO Year | 2013 | 1995 |
| Metric | AR | TECH |
|---|---|---|
| Price | $35.17 | $72.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 11 |
| Target Price | $47.13 | ★ $71.82 |
| AVG Volume (30 Days) | 4.3M | ★ 4.8M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 0.62% |
| EPS Growth | ★ 1027.78 | N/A |
| EPS | ★ 1.72 | 0.81 |
| Revenue | ★ $5,275,823,000.00 | $1,219,635,000.00 |
| Revenue This Year | $29.74 | $2.49 |
| Revenue Next Year | $5.07 | $6.40 |
| P/E Ratio | ★ $19.69 | $88.99 |
| Revenue Growth | ★ 21.97 | 5.23 |
| 52 Week Low | $29.10 | $43.20 |
| 52 Week High | $45.75 | $72.16 |
| Indicator | AR | TECH |
|---|---|---|
| Relative Strength Index (RSI) | 53.26 | 74.31 |
| Support Level | $32.82 | $70.49 |
| Resistance Level | $35.86 | $72.14 |
| Average True Range (ATR) | 1.00 | 0.36 |
| MACD | 0.14 | -0.65 |
| Stochastic Oscillator | 72.87 | 88.64 |
Antero Resources is an exploration and production firm whose operations represent a pure play in the Marcellus Shale, located in northern West Virginia. The company started in 2002 as an E&P focused on the Barnett Shale (Fort Worth, Texas). Antero redefined itself in Appalachia's Marcellus Shale in 2005. In 2012, shortly before Antero's 2013 IPO, Antero Midstream Partners was formed to handle the company's rapidly growing gas volumes. In 2026, the firm narrowed its focus further by selling its Ohio Utica assets and using the proceeds to acquire additional Marcellus acreage from HG Energy. Just over half of its production and earning power is tied to natural gas, with the remainder mostly NGLs, where it holds a leading position, and some crude oil.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.